International journal of clinical practice. Supplement最新文献_第10页

Research advances in the treatment of type 2 diabetes mellitus. 2型糖尿病治疗的研究进展。

International journal of clinical practice. Supplement Pub Date : 1999-09-01

J Caro, K L Wishner

引用次数: 0

The role of insulin treatment in type 2 diabetes. 胰岛素治疗在2型糖尿病中的作用。

International journal of clinical practice. Supplement Pub Date : 1999-09-01

S Del Prato

引用次数: 0

Optimisation of insulin treatment to improve cardiovascular risk. 优化胰岛素治疗以提高心血管风险。

International journal of clinical practice. Supplement Pub Date : 1999-09-01

A De Leiva

引用次数: 0

State of current therapy and patient care in Europe. 欧洲目前的治疗和病人护理状况。

International journal of clinical practice. Supplement Pub Date : 1999-09-01

P J Lefebvre, A J Scheen

引用次数: 0

The importance of postprandial hyperglycaemia. 餐后高血糖的重要性。

International journal of clinical practice. Supplement Pub Date : 1999-09-01

J R Gavin

引用次数: 0

Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. 急性偏头痛患者口服舒马曲坦25mg、50mg或100mg的偏好:一项双盲、随机、交叉研究舒马曲坦片S2CM11研究组。

International journal of clinical practice. Supplement Pub Date : 1999-08-01

R Salonen, E A Ashford, M Gibbs, H Hassani

{"title":"Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.","authors":"R Salonen, E A Ashford, M Gibbs, H Hassani","doi":"","DOIUrl":"","url":null,"abstract":"Background: Dosing recommendations for oral sumatriptan have ranged from 25 mg to 100 mg. Patient dose preferences are clinically relevant (perhaps moreso than traditional efficacy endpoints) and deserve study.Methods: A multinational randomized double-blind crossover study was conducted over 18 weeks to assess patient dose preference, efficacy, and tolerability for oral sumatriptan (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine; 257 patients treated three attacks, using a different dose for each.Results: The 100 mg dose was preferred by 35% of patients, 31% the 50 mg dose, and 25% the 25 mg dose. Efficacy and speed of action were the two main reasons given for preferring the higher doses. Compared with the 25 mg dose, the 100 mg and 50 mg doses were significantly more likely to provide headache relief at 2, 3, and 4 h after dosing and complete headache resolution at 3 and 4 h after dosing (P < 0.027). Recurrence rates were similar for the three doses, ranging from 33% to 38%, though the median time to recurrence increased with dose, from 8.5 to 11.8 h. The 25 mg, 50 mg, and 100 mg doses were all well tolerated, with adverse event incidences of 19%, 21%, and 30%, respectively.Conclusions: Patients preferred the 50 mg and 100 mg doses of oral sumatriptan to the 25 mg dose, and the higher doses were more effective against migraine; however, the 25 mg and 50 mg doses were better tolerated than the 100 mg dose. Though the 50 mg dose probably has the best effectiveness-to-tolerability ratio, some patients clearly prefer a higher dose.","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining optimal dosing for sumatriptan tablets in the acute treatment of migraine. 确定舒马曲坦片在偏头痛急性治疗中的最佳剂量。

International journal of clinical practice. Supplement Pub Date : 1999-08-01

N T Mathew, R Salonen

引用次数: 0

A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. 一项双盲安慰剂对照研究评估50mg舒马普坦片急性治疗偏头痛的疗效和耐受性。舒马曲坦片S2CM07研究组。

International journal of clinical practice. Supplement Pub Date : 1999-08-01

N Savani, N J Brautaset, M Reunanen, I Szirmai, E A Ashford, H Hassani, J Saiers

{"title":"A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group.","authors":"N Savani, N J Brautaset, M Reunanen, I Szirmai, E A Ashford, H Hassani, J Saiers","doi":"","DOIUrl":"","url":null,"abstract":"Background: Oral sumatriptan 50 mg has been found to have good efficacy and tolerability in the acute treatment of migraine but has been less well studied than the 100 mg dose.Methods: This was a double-blind, parallel-group study (Glaxo Wellcome protocol number S2CM07) comparing the efficacy and safety of sumatriptan 50 mg tablets with placebo in the acute treatment of migraine. Patients treated three migraine attacks with study medication; a second, optional dose was available for treating recurrent headache. Of the 560 patients randomized, 485 treated at least one attack, 411 at least two attacks, and 362 three attacks. The primary efficacy measure was the proportion of patients who had obtained complete or almost complete headache relief at 4 h after dosing.Results: For all attacks, a significantly greater proportion of patients experienced headache relief at 4 h with sumatriptan 50 mg tablets than with placebo (59% to 62% versus 32% to 42%; P = 0.005). The same was true at 3 h across all attacks, and at 2 h for attacks 1 and 2 (49% versus 23% and 45% versus 29%, respectively). Although sumatriptan and placebo were associated with similar incidences of recurrence, sumatriptan was associated with a longer time to recurrence. The incidence of adverse events with sumatriptan was similar to that with placebo, and there was no increase in adverse events associated with use of a second dose to treat recurrence.Conclusions: Sumatriptan 50 mg tablets are well tolerated and efficacious in relieving migraine headache.","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group. 为期六个月的开放标签研究中评估口服舒马曲坦急性治疗偏头痛的患者选择剂量。舒马曲坦片S2CM10研究组。

International journal of clinical practice. Supplement Pub Date : 1999-08-01

A J Dowson, E A Ashford, S Prendergast, H Hassani, G W Roberts, T Flöter, A Szczudlik

{"title":"Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group.","authors":"A J Dowson, E A Ashford, S Prendergast, H Hassani, G W Roberts, T Flöter, A Szczudlik","doi":"","DOIUrl":"","url":null,"abstract":"Background: Dosing recommendations for oral sumatriptan as acute treatment for migraine have ranged from 25 mg to 100 mg. Patient dose preferences have not been studied in a setting mimicking clinical practice.Methods: In an open-label study evaluating patient acceptance and the relative efficacy and safety of 25 mg, 50 mg, and 100 mg doses of oral sumatriptan over a period of six months, 338 patients treated three migraine attacks with 50 mg sumatriptan and then were allowed to double or halve the dose. After treating another three attacks, they were again allowed to adjust the dose by one level.Results: After migraine attack 3, 37% of patients chose to continue with the 50 mg dose, 50% increased the dose to 100 mg, and 12% decreased it to 25 mg. After attack 6, 8%, 33%, and 58% of patients chose the 25 mg, 50 mg, and 100 mg doses, respectively; only 3% of those taking the 100 mg dose chose to reduce it. Overall, the mean percentages of attacks per patient in which headache relief had been obtained 4 h after dosing were 71%, 71%, and 80% for the 25 mg, 50 mg, and 100 mg doses, respectively. Patients who decreased the dose to 25 mg after attack 3 experienced decreases both in adverse events and percentage of attacks with headache relief, whereas in those who increased the dose to 100 mg, likelihood of headache relief increased but the incidence of adverse events did not.Conclusions: More patients chose the 50 mg or 100 mg dose than the 25 mg dose. All three doses had similar efficacy and tolerability.","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postprandial hyperglycaemia--its importance and implications. 餐后高血糖——它的重要性和意义。

International journal of clinical practice. Supplement Pub Date : 1999-07-01

H J Lüddeke

引用次数: 0